Cite
HARVARD Citation
Chanchlani, N. et al. (2022). Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients. Journal of Crohn's and colitis. pp. 389-397. [Online].